Skip to content

The Product

mCRP-ALISA™ — a quantitative readout for monomeric CRP

A microplate assay built to fit the workflows labs already run, engineered around a binder that sees the active form of CRP.

Aptamer-basedCompetitive ALISASerum96-wellIn development (RUO)

At a glance

What's in the kit

ComponentSpecification
mCRP-coated microplate96-well, COOH-activated; mCRP immobilised
Biotinylated Sentos binderWorking range ~0.3–4.8 µg/mL; specific for mCRP (KD ≈ 151 nM)
Detection systemStreptavidin-HRP conjugate; TMB substrate; acid stop solution
Buffers & solutionsAptamer binding buffer; PBS-Tween wash; blocking solution
Quality controlsPositive control (recombinant mCRP, 100 ng/mL); negative control (pooled normal serum); multi-point reference standards
Configuration reflects the development-stage kit and may change through validation and regulatory review.

Workflow

Designed for the lab bench

A single-plate, colorimetric workflow that maps onto standard ELISA-style processing — no specialised reader beyond a standard microplate spectrophotometer. TODO: final assay time target for public claim

  1. 1

    Prepare

    thaw reagents; lay out standards, controls, and samples.

  2. 2

    Incubate

    competitive binding of sample and plate-bound mCRP for the aptamer.

  3. 3

    Wash & develop

    remove unbound material; add streptavidin-HRP and TMB.

  4. 4

    Read

    colorimetric measurement; interpolate mCRP from the standard curve.

Performance & specifications

Specifications (development-stage)

ParameterValue
Target analyteMonomeric C-reactive protein (mCRP)
Sample typeHuman serum
Limit of detectionApproximately 100 ng/mL in serum
Specificity>95% discrimination vs pCRP
Cross-reactivity<5% vs pCRP; <1% vs common serum proteins
Coated-plate stability12 weeks at 2–8 °C (validated)
Extended-stability target18-month stabilised shelf life — development target under evaluation TODO: Not yet validated
Format96-well microplate, competitive ALISA, colorimetric

Regulatory status

Why it's different

Three advantages that compound

01

A specific target.

Most inflammation tests measure total/pentameric CRP. Ours is built to measure the monomeric, tissue-active form.

02

Aptamer chemistry.

Synthetic, reproducible, and robust — with a favourable cost structure at scale versus antibody-based assays.

03

A workflow labs already know.

A microplate competitive immunoassay that slots into existing lab operations.

Roadmap (product formats)

From microplate to point of care

The microplate assay is the first format. Our development roadmap includes a point-of-care configuration and multiplex panels that pair mCRP with complementary inflammatory markers. These are in development and not yet available. TODO: which roadmap items are public